These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15968563)

  • 21. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
    Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
    Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions.
    Nan Luo ; Johnson JA; Shaw JW; Coons SJ
    Med Decis Making; 2007; 27(3):321-6. PubMed ID: 17545501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the validity of two indirect utility instruments as measures of postoperative recovery.
    Lee L; Mata J; Augustin BR; Carli F; Morin N; Latimer E; Feldman LS
    J Surg Res; 2014 Jul; 190(1):79-86. PubMed ID: 24629417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The classification systems of the EQ-5D, the HUI II and the SF-6D: what do they have in common?
    Konerding U; Moock J; Kohlmann T
    Qual Life Res; 2009 Nov; 18(9):1249-61. PubMed ID: 19728160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How consistent are health utility values?
    Ferreira PL; Ferreira LN; Pereira LN
    Qual Life Res; 2008 Sep; 17(7):1031-42. PubMed ID: 18688757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study.
    Pickles K; Lancsar E; Seymour J; Parkin D; Donaldson C; Carter SM
    Soc Sci Med; 2019 Nov; 240():112560. PubMed ID: 31563007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.
    Visser MS; Amarakoon S; Missotten T; Timman R; Busschbach JJ
    PLoS One; 2017; 12(2):e0169816. PubMed ID: 28225799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
    Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of Hong Kong and United Kingdom SF-6D health states valuations using a nonparametric Bayesian method.
    Kharroubi SA; Brazier JE; McGhee S
    Value Health; 2014 Jun; 17(4):397-405. PubMed ID: 24969000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets.
    Tsuchiya A; Brazier J; Roberts J
    J Health Econ; 2006 Mar; 25(2):334-46. PubMed ID: 16271783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variation in the estimation of quality-adjusted life-years by different preference-based instruments.
    Conner-Spady B; Suarez-Almazor ME
    Med Care; 2003 Jul; 41(7):791-801. PubMed ID: 12835603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The DEP-6D, a new preference-based measure to assess health states of dependency.
    Rodríguez-Míguez E; Abellán-Perpiñán JM; Alvarez XC; González XM; Sampayo AR
    Soc Sci Med; 2016 Mar; 153():210-9. PubMed ID: 26921836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring population health: a comparison of three generic health status measures.
    Macran S; Weatherly H; Kind P
    Med Care; 2003 Feb; 41(2):218-31. PubMed ID: 12555050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning.
    Günther OH; Roick C; Angermeyer MC; König HH
    J Affect Disord; 2008 Jan; 105(1-3):81-91. PubMed ID: 17532051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the SF-6D value set for a population-based sample of Brazilians.
    Cruz LN; Camey SA; Hoffmann JF; Rowen D; Brazier JE; Fleck MP; Polanczyk CA
    Value Health; 2011; 14(5 Suppl 1):S108-14. PubMed ID: 21839880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the performance of the EQ-5D and SF-6D for individuals aged >or= 45 years.
    Barton GR; Sach TH; Avery AJ; Jenkinson C; Doherty M; Whynes DK; Muir KR
    Health Econ; 2008 Jul; 17(7):815-32. PubMed ID: 17893863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the EQ-5D and SF-6D across seven patient groups.
    Brazier J; Roberts J; Tsuchiya A; Busschbach J
    Health Econ; 2004 Sep; 13(9):873-84. PubMed ID: 15362179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort.
    Gaujoux-Viala C; Rat AC; Guillemin F; Flipo RM; Fardellone P; Bourgeois P; Fautrel B
    Ann Rheum Dis; 2012 Sep; 71(9):1478-83. PubMed ID: 22419775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.